University of Cambridge > > HDR UK Cambridge Seminar Series > Genetics for drug discovery, going beyond target ID

Genetics for drug discovery, going beyond target ID

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Spencer Keene.

Please sign up at:

At Novo Nordisk, we have a human centric approach to drug discovery, for example by harnessing human genetics and integrating other omics and data types to identify potential targets in cardiometabolic diseases. That targets with human genetics support are more likely to be successful in clinical development, is well established. What is less often discussed is, can we further leverage human data to help develop therapies for patients? I will highlight a few examples of what we are thinking about in relation to using human genetics at Novo Nordisk, beyond target identification.

This talk is part of the HDR UK Cambridge Seminar Series series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2024, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity